Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 4 on this page, newest registry updates first. Search checked 2026-10-07 19:34 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 2CompletedINTERVENTIONAL

Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes

ClinicalTrials.gov · NCT04982575 · Registry updated: 2025-12-23

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: Novo Nordisk A/S
Countries with listed sites: United States
Registry dates and results: Start: 2021-08-02. Completion: 2022-07-07 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide 2.4 mg (drug)
Cagrilintide 2.4 mg (drug)
Placebo (semaglutide) (drug)
Placebo (cagrilintide) (drug)

Where the study takes place — 23 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Uni of Alabama at Birmingham
Birmingham, Alabama, United States
Site recruitment: Not reported
Valley Research
Fresno, California, United States
Site recruitment: Not reported
Pacific Clinical Studies
Los Alamitos, California, United States
Site recruitment: Not reported
Velocity Clin Res Los Angeles
Los Angeles, California, United States
Site recruitment: Not reported
Encompass Clinical Research_Spring Valley
Spring Valley, California, United States
Site recruitment: Not reported
New West Physicians,Inc.
Golden, Colorado, United States
Site recruitment: Not reported
FPA Clinical Research
Kissimmee, Florida, United States
Site recruitment: Not reported
Florida Inst For Clin Res
Orlando, Florida, United States
Site recruitment: Not reported
Clinical Trial Res Assoc,Inc
Plantation, Florida, United States
Site recruitment: Not reported
Ellipsis Group
Alpharetta, Georgia, United States
Site recruitment: Not reported
East West Med Res Inst
Honolulu, Hawaii, United States
Site recruitment: Not reported
Macoupin Research Group
Gillespie, Illinois, United States
Site recruitment: Not reported
MD Medical Research
Oxon Hill, Maryland, United States
Site recruitment: Not reported
PharmQuest Life Sciences LLC
Greensboro, North Carolina, United States
Site recruitment: Not reported
Accellacare
Wilmington, North Carolina, United States
Site recruitment: Not reported
Lillestol Research LLC
Fargo, North Dakota, United States
Site recruitment: Not reported
Plains Clinical Research Center, LLC_Fargo
Fargo, North Dakota, United States
Site recruitment: Not reported
Holston Medical Group
Kingsport, Tennessee, United States
Site recruitment: Not reported
Velocity Clinical Res-Dallas
Dallas, Texas, United States
Site recruitment: Not reported
PlanIt Research, PLLC
Houston, Texas, United States
Site recruitment: Not reported
DCOL Ctr for Clin Res
Longview, Texas, United States
Site recruitment: Not reported
Selma Medical Associates
Winchester, Virginia, United States
Site recruitment: Not reported
Capital Clin Res Ctr,LLC
Olympia, Washington, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function and How Cagrilintide is Absorbed and Used by the Body

ClinicalTrials.gov · NCT05564104 · Registry updated: 2025-12-12

Condition / research focus: Hepatic Impairment; Healthy Volunteers
Sponsor: Novo Nordisk A/S
Countries with listed sites: Czechia · Germany · Slovakia
Registry dates and results: Start: 2023-04-05. Completion: 2024-12-19 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Cagrilintide (drug) — also listed as: NNC0174-0833

Where the study takes place — 4 listed sites

Pharmaceutical Research Associates CZ, s.r.o.
Prague, Czechia
Site recruitment: Not reported
APEX Research
München, Germany
Site recruitment: Not reported
Summit Clinical Research s.r.o.
Bratislava, Slovakia
Site recruitment: Not reported
Summit Clinical Research s.r.o.
Malacky, Slovakia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity

ClinicalTrials.gov · NCT04940078 · Registry updated: 2025-12-12

Condition / research focus: Obesity & Overweight
Sponsor: Novo Nordisk A/S
Countries with listed sites: Canada · Denmark
Registry dates and results: Start: 2021-07-07. Completion: 2022-02-16 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Cagrilintide (drug)
semaglutide (drug)
Cagrilintide and semaglutide (drug)

Where the study takes place — 2 listed sites

Altasciences Company Inc.
Montreal, Quebec, Canada
Site recruitment: Not reported
Novo Nordisk Investigational Site
Søborg, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy Participants

ClinicalTrials.gov · NCT05804162 · Registry updated: 2024-11-01

Condition / research focus: Obesity
Sponsor: Novo Nordisk A/S
Countries with listed sites: Germany
Registry dates and results: Start: 2023-04-12. Completion: 2023-09-18 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Cagrilintide (drug) — also listed as: Cagrilintide A, NNC0174-0833 A
Cagrilintide Placebo (drug) — also listed as: Cagrilintide A, NNC0174-0833 A
Moxifloxacin (drug) — also listed as: Moxifloxacinratiopharm
Moxifloxacin Placebo (drug)

Where the study takes place — 1 listed sites

Parexel International GmbH
Berlin, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 4 on this page, newest registry updates first. Search checked 2026-10-07 19:34 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 2CompletedINTERVENTIONAL

Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes

ClinicalTrials.gov · NCT04982575 · Registry updated: 2025-12-23

Condition / research focus: Diabetes Mellitus, Type 2
Sponsor: Novo Nordisk A/S
Countries with listed sites: United States
Registry dates and results: Start: 2021-08-02. Completion: 2022-07-07 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Semaglutide 2.4 mg (drug)
Cagrilintide 2.4 mg (drug)
Placebo (semaglutide) (drug)
Placebo (cagrilintide) (drug)

Where the study takes place — 23 listed sites

Uni of Alabama at Birmingham
Birmingham, Alabama, United States
Site recruitment: Not reported
Valley Research
Fresno, California, United States
Site recruitment: Not reported
Pacific Clinical Studies
Los Alamitos, California, United States
Site recruitment: Not reported
Velocity Clin Res Los Angeles
Los Angeles, California, United States
Site recruitment: Not reported
Encompass Clinical Research_Spring Valley
Spring Valley, California, United States
Site recruitment: Not reported
New West Physicians,Inc.
Golden, Colorado, United States
Site recruitment: Not reported
FPA Clinical Research
Kissimmee, Florida, United States
Site recruitment: Not reported
Florida Inst For Clin Res
Orlando, Florida, United States
Site recruitment: Not reported
Clinical Trial Res Assoc,Inc
Plantation, Florida, United States
Site recruitment: Not reported
Ellipsis Group
Alpharetta, Georgia, United States
Site recruitment: Not reported
East West Med Res Inst
Honolulu, Hawaii, United States
Site recruitment: Not reported
Macoupin Research Group
Gillespie, Illinois, United States
Site recruitment: Not reported
MD Medical Research
Oxon Hill, Maryland, United States
Site recruitment: Not reported
PharmQuest Life Sciences LLC
Greensboro, North Carolina, United States
Site recruitment: Not reported
Accellacare
Wilmington, North Carolina, United States
Site recruitment: Not reported
Lillestol Research LLC
Fargo, North Dakota, United States
Site recruitment: Not reported
Plains Clinical Research Center, LLC_Fargo
Fargo, North Dakota, United States
Site recruitment: Not reported
Holston Medical Group
Kingsport, Tennessee, United States
Site recruitment: Not reported
Velocity Clinical Res-Dallas
Dallas, Texas, United States
Site recruitment: Not reported
PlanIt Research, PLLC
Houston, Texas, United States
Site recruitment: Not reported
DCOL Ctr for Clin Res
Longview, Texas, United States
Site recruitment: Not reported
Selma Medical Associates
Winchester, Virginia, United States
Site recruitment: Not reported
Capital Clin Res Ctr,LLC
Olympia, Washington, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function and How Cagrilintide is Absorbed and Used by the Body

ClinicalTrials.gov · NCT05564104 · Registry updated: 2025-12-12

Condition / research focus: Hepatic Impairment; Healthy Volunteers
Sponsor: Novo Nordisk A/S
Countries with listed sites: Czechia · Germany · Slovakia
Registry dates and results: Start: 2023-04-05. Completion: 2024-12-19 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Cagrilintide (drug) — also listed as: NNC0174-0833

Where the study takes place — 4 listed sites

Pharmaceutical Research Associates CZ, s.r.o.
Prague, Czechia
Site recruitment: Not reported
APEX Research
München, Germany
Site recruitment: Not reported
Summit Clinical Research s.r.o.
Bratislava, Slovakia
Site recruitment: Not reported
Summit Clinical Research s.r.o.
Malacky, Slovakia
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity

ClinicalTrials.gov · NCT04940078 · Registry updated: 2025-12-12

Condition / research focus: Obesity & Overweight
Sponsor: Novo Nordisk A/S
Countries with listed sites: Canada · Denmark
Registry dates and results: Start: 2021-07-07. Completion: 2022-02-16 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Cagrilintide (drug)
semaglutide (drug)
Cagrilintide and semaglutide (drug)

Where the study takes place — 2 listed sites

Altasciences Company Inc.
Montreal, Quebec, Canada
Site recruitment: Not reported
Novo Nordisk Investigational Site
Søborg, Denmark
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy Participants

ClinicalTrials.gov · NCT05804162 · Registry updated: 2024-11-01

Condition / research focus: Obesity
Sponsor: Novo Nordisk A/S
Countries with listed sites: Germany
Registry dates and results: Start: 2023-04-12. Completion: 2023-09-18 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Cagrilintide (drug) — also listed as: Cagrilintide A, NNC0174-0833 A
Cagrilintide Placebo (drug) — also listed as: Cagrilintide A, NNC0174-0833 A
Moxifloxacin (drug) — also listed as: Moxifloxacinratiopharm
Moxifloxacin Placebo (drug)

Where the study takes place — 1 listed sites

Parexel International GmbH
Berlin, Germany
Site recruitment: Not reported

Original record, eligibility, contacts and results →